由SGLT2抑制剂诱导的原始细胞功能和心血管重塑
Theodora M Stougiannou1, Konstantinos C Christodoulou1, Theocharis Koufakis2
1Department of Cardiothoracic Surgery, Democritus University of Thrace - University General Hospital, 68100 Alexeandroupolis, Greece.
Frontiers in bioscience (Landmark edition)
|April 29, 2024
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 通过积极影响心脏重塑,显示出心脏保护作用. 这些SGLT2抑制剂可以通过调节干细胞和前代细胞,包括内皮前代细胞 (EPC) 来改善心血管健康.
科学领域:
- 心血管科学 心血管科学
- 脏生理学 脏生理学
- 内分泌学 在内分泌学.
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂,最初用于2型糖尿病,现在治疗心力衰竭和脏疾病.
- 心血管改造涉及由于受伤或压力的分子和细胞变化.
- 干细胞和前代细胞,特别是内皮前代细胞 (EPC),在病理重塑中发挥作用.
研究的目的:
- 在心脏改造的背景下,审查SGLT2抑制剂的心脏保护作用.
- 批判性地讨论最近关于SGLT2抑制剂的证据及其对心血管疾病的影响.
- 探索SGLT2抑制剂在调节干细胞和祖细胞中的潜在作用.
主要方法:
- 现有科学文献的叙述性审查.
- 对研究SGLT2抑制剂对心脏重塑的影响的研究分析.
- 检查研究SGLT2抑制剂对干细胞和祖细胞 (包括EPCs) 的影响.
主要成果:
- SGLT2 抑制剂在心脏重塑过程中对分子和细胞变化产生积极影响.
- 有证据表明,SGLT2抑制剂可以调节内皮前细胞 (EPC) 的形态和功能.
- 观察到对EPC的影响可能有助于与SGLT2抑制剂相关的有益心血管结果.
结论:
- SGLT2 抑制剂提供了超出血糖控制的显著心脏保护益处.
- 干细胞和祖细胞的调节,特别是EPCs,是SGLT2抑制剂疗效的潜在机制.
- 需要进一步的研究,以充分阐明SGLT2抑制剂在心血管疾病预防和治疗中的作用.
相关概念视频
01:22iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
01:23Tissue Renewal without Stem Cells
1.7K
After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...
However, failure of such a system...
1.7K